塞来昔布联合XELOX方案治疗晚期胃癌的临床研究

Clinical study on celecoxib combined with XELOX regimen in the treatment of advanced gastric cancers

目的:评价塞来昔布联合XELOX方案治疗晚期胃癌的临床疗效及安全性。方法:选取2015年5月至2016年8月河源市人民医院收治的晚期胃癌患者48例作为研究对象,随机分为对照组(XELOX方案)和试验组(XELOX-C,塞来昔布联合XELOX方案)。21 d为1个周期,治疗2个周期后评价近期疗效与不良反应。结果:对照组有效率37.5%,疾病控制率66.7%;试验组有效率54.2%,疾病控制率91.7%,两组比较,差异均无统计学意义(P>0.05)。两组白细胞减少、贫血、血小板减少、恶心、呕吐、腹泻、口腔黏膜炎及外周神经炎等不良反应发生率比较,差异无统计学意义(P>0.05),但试验组手足综合征发生率明显低于对照组(P<0.05)。结论:塞来昔布联合XELOX方案治疗晚期胃癌可以改善患者的手足综合征,耐受性良好。

Objective：To evaluate the clinical efficacy and safety of celecoxib combined with XELOX regimen in the treatment of advanced gastric cancers. Methods：Included in this study were 48 patients with advanced gastric cancers treated in Heyuan People＇s Hospital betweeen May 2015 to August 2016.These patients were randomly divided into the control group （on XELOX regimen） and the study group （on XELOX-C regimen, i.e.celecoxib combined with XELOX）. Each treatment cycle consisted of 21 d. After 2 treatment cycles, the patients were evaluated for short-term efficacy and adverse reaetions. Results： The rates of effectiveness and disease control were 37.5% and 66.7%, respectively,in the control group, compared with 54.2% and 91.7% in the study group.There were no significant differences in these rates between the two groups （P〉O. 05 ）. The two groups did not differ significantly in the incidence of adverse reactions such as leukopenia, anemia, thrombocytopenia, nausea, vomiting, diarrhea, oral mueositis and peripheral neuritis （ P 〉 0.05 ）. However, incidence of hand-foot syndrome was lower in the study group than in the control group （P〈0.05）. Conclusion： Celecoxib combined with XELOX regimen as a treatment of advanced gastric cancer may lead to improvement in hand-foot syndrome and good tolerability.